LONDON, UNITED KINGDOM - (NewMediaWire) - May 24, 2016 - Plandaí Biotechnology, Inc. (OTCQB: PLPL) ("Plandaí" or "the Company"), producer of the highly bioavailable Phytofare® catechin complex, today announced that it will be expanding the previously announced clinical trial involving poultry to also include a Phytofare® catechin-proPheroid® formulation in grain-based pellets. If successful, this new delivery method could open the door for introducing pH2™ catechins, rich in antioxidants and omega 3 and 6 fatty acids as a wellness food supplement, for various livestock animals, such as poultry and bovines, and pets, including hooved animals, dogs, cats and birds.

In a previously announced clinical trial, Plandaí completed the initial study with pH2™ catechins formulated in water to determine the efficacy levels in slaughter chicken plasma. Based on these findings, the new investigations will determine the levels of pH2™ catechin absorption through formulation into animal feed. This new approach has the potential to a provide an efficient method of controlling and protecting the clinical dosage of pH2™ catechins to the animal's blood plasma

Roger Baylis-Duffield, Chief Executive Officer, commented, "Animals obviously have a different morphology than humans. Their digestive and metabolization processes vary greatly. Poultry, for example, lacking teeth, rely on much stronger stomach acids than humans. These differences pose a unique set of challenges when trying to deliver a botanical supplement through ingestion.

"Fortunately," added Mr. Baylis-Duffield, "the scientific team have developed proprietary methodologies for formulating pH2™ catechins into animal feed, thus preserving the antioxidant activities of Phytofare® catechins. This system opens the door for Plandaí to investigate wellness applications across various agricultural areas, including dairy and beef production, where illnesses such as brucellosis significantly impact the industry. Previous studies have also indicated the benefits of Pheroid® in increasing milk production. For pets, including dogs, cats, birds and hooved animals, delivering a clinical dose of Phytofare® into their diet could help fight against infectious diseases, insect borne pathogens (from ticks, mosquitoes, etc.), cancers, diabetes, and the like. Our objective is to clinically prove that pH2 catechins can provide a solution for reducing the agriculture industry's current reliance on antibiotics and other synthetic treatment protocols in commercial farming by incorporating all natural, organic botanical products directly into the animals' feed."

The first phase of the new 3-phase poultry investigation is scheduled to commence in the second half of June following Ethics committee approval. The collective studies are designed to clinically demonstrate that pH2™ catechins are protected and delivered to the animals' blood plasma with overall benefits relating to improved wellness, reduced mortality levels and the reduction of the commercial growing life-cycle of the slaughter chicken.

About Plandaí Biotechnology, Inc.

Plandaí Biotechnology, Inc. and its subsidiaries develop highly phyto-available™ extracts. Plandaí Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing its proprietary Phytofare® extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include beverage, cosmeceutical, wellness, nutriceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com.

Safe Harbor Statement

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Readers are advised to review our filings with the Securities and Exchange Commission that can be accessed over the Internet at the SEC's website located at http://www.sec.gov.